Trauma patients are at a high risk of both bleeding and thromboembolism. This study assessed whether conventional coagulation blood tests were reliable predictors of an increased in vitro thrombotic and bleeding tendency of trauma and non-trauma patients. Conventional coagulation blood tests and thromboelastographs of 63 trauma and 63 randomly selected, critically ill non-trauma patients were compared. Increased in vitro thrombotic and bleeding tendencies were defined by a maximum amplitude >72 mm or an angle >74° on the thromboelastograph and a maximum amplitude < 54 mm or an angle <47°, respectively. In vitro thrombotic tendency was more common than bleeding tendency and this was not different between the critically ill trauma and non-trauma patients (59% versus 67% with thrombotic tendency, P=0.461; 11% versus 10% with bleeding tendency, respectively, P=0.999). Thrombocytopenia (<150 x 10 9 /l) and low fibrinogen concentrations (<2 g/l) were the only two factors associated with an increased in vitro bleeding tendency (both P=0.001) and thrombocytopenia was the only factor associated with a lower risk of in vitro thrombotic tendency (21% versus 75%, P=0.001). Platelet counts (Pearson's correlation coefficient [r]: 0.59, P=0.001) and fibrinogen concentrations (r 0.61, P=0.001) both had a relatively linear association with maximum amplitude of the thromboelastograph. Prolonged International Normalized Ratio (>1.5) and activated Partial Thromboplastin Time (>40 seconds) were, however, not significantly associated with an increased in vitro thrombotic or bleeding tendency. In conclusion, in vitro thrombotic tendency was more common than bleeding tendency in critically ill trauma and non-trauma patients. Platelet counts and fibrinogen concentrations were better predictors of increased in vitro thrombotic and bleeding risks than International Normalized Ratio or activated Partial Thromboplastin Time.
Both bleeding and venous thromboembolism (VTE) are common complications after major trauma. Guidelines from the American College of Chest Physicians have suggested that pharmacological VTE prophylaxis should be used for patients at high risk of VTE, including critically ill or major trauma patients 1 . However, the clinical concern about excessive haemorrhage persists, especially for patients who have significant risk of bleeding after trauma or those with significant acquired coagulopathy. Many clinicians perceive the risk of bleeding as more important than the risk of VTE, particularly for patients who are at high risk of bleeding and have acquired coagulopathy after major surgery or severe trauma 2, 3 . Evidence suggests that a delay of >3 days in initiating pharmacological VTE prophylaxis increases the risk of VTE by threefold in patients after major trauma 4 . The incidence of asymptomatic pulmonary embolism between three and seven days after moderate to major trauma is indeed extremely high (24%) 5 and use of pneumatic lower limb compression devices alone may not be completely effective in preventing VTE 5, 6 . Fatal pulmonary embolism is the third leading cause of death in patients who survive the first 24 hours after major trauma 7 and this may, in part, be due to omission of VTE prophylaxis because of concern about the risk of bleeding or presence of acquired coagulopathy 8, 9 . The traditional belief that patients with an abnormal coagulation profile or thrombocytopenia are at risk of bleeding, but not VTE, has recently been challenged. Multiple studies have shown that patients with an abnormal coagulation profile from advanced liver disease have a similar risk of VTE compared to those without liver disease or those with mild liver disease with a normal coagulation profile 10 . Critically ill patients with cirrhosis and an abnormal coagulation profile (International Normalized Ratio [INR]: 2.2 ± 0.9 versus 1.3 ± 0.6, P <0.0001; platelet count: 115 versus 258×10 9 /l, P <0.0001, respectively) had a very similar incidence of symptomatic VTE compared to those critically ill patients without cirrhosis (2.2 events per 1000 patientintensive care unit [ICU] days for cirrhotic patients and 3.6 events per 1000 patient-ICU days for patients without cirrhosis; incidence ratio, 0.61; 95% confidence interval [CI]: 0.15 to 2.52) 11 . This counter-intuitive observation may be due to the fact that standard conventional coagulation tests, including INR and activated Partial Thromboplastin Time (aPTT), do not measure the whole coagulation and anticoagulation cascades in a comprehensive fashion.
We hypothesised that in critically ill patients, in vitro thrombotic or bleeding tendency may not be accurately predicted by the standard haematological and coagulation tests (e.g. INR, aPTT, platelet counts or fibrinogen concentrations), and that this situation was not different between trauma and non-trauma patients. In this study, we aimed to assess whether conventional coagulation blood tests were reliable predictors of an increased in vitro thrombotic and bleeding tendency of trauma and non-trauma critically ill patients and whether an increased risk of in vitro thrombotic tendency was associated with an increased risk of subsequent symptomatic VTE.
Methods
After obtaining Royal Perth Hospital Ethics Committee approval (Approval No.: 98/2009), this prospective study recruited patients who had been admitted to the ICU for more than 48 hours and were not actively bleeding at the time of study enrolment. Royal Perth Hospital is Western Australia's State Trauma Centre and the ICU admits over 1500 critically ill trauma and non-trauma patients per year.
Because of the observational nature and the small amount of blood needed for this study, informed consent was waived by the ethics committee. In this study, we randomly recruited one non-trauma patient in the ICU for each trauma patient recruited, without using matching. We planned a sample size of 60 in each group, assuming 30% had either a prothrombotic or bleeding tendency, allowing us to adjust for four covariates in the multivariate analysis.
In this study, in vitro thrombotic and bleeding tendency was assessed using the maximum amplitude (MA) (normal range: 54 to 72 mm) and angle (normal range 47 to 74°) of the thromboelastograph (TEG) (TEG 5000 Thromboelastograph ® Haemostasis Analyzer, Medtel, Lane Cove, NSW). The TEG provides a comprehensive in vitro evaluation of the overall coagulation function of the whole blood sample 12 . According to the recommendation of the manufacturer of the TEG machine, an MA >72 mm or an angle >74° was regarded as having an increased in vitro thrombotic tendency and an MA <54 mm or an angle <47° was considered as having an increased in vitro bleeding tendency. Two channels of TEG, one using kaolin alone as the activating agent and the other using kaolin with heparinase, were conducted for all study patients. All wholeblood samples were tested within four minutes of sampling at the patient's body temperature. Because some study patients might have received unfractionated heparin subcutaneously for VTE prophylaxis, TEG data on the MA of the TEG tracing from the heparinase channel were used for all patients for consistency. The quantitative relationships between INR, aPTT, platelet counts or fibrinogen concentrations and MA on the TEG were analysed by scatter plots, and Pearson's correlation coefficient (r) was used to assess the degree of linear relationships between these variables. The relationships between thrombocytopenia (platelet counts <150×10 9 /l), prolonged INR (>1.5), prolonged aPTT (>40 seconds) or a low fibrinogen concentration (<2 g/l) and evidence of either an increased in vitro thrombotic (MA >72 mm) or bleeding (MA <54 mm) tendency were analysed by multivariate logistic regression without removal of predictors. Differences between categorical or continuous variables with skewed distributions were assessed by a chi-square and Mann-Whitney U test, respectively.
As a sensitivity analysis, we also assessed whether correlations between MA and INR or aPTT were different after logarithm transformation and whether the logarithms of INR and aPTT were predictive of in vitro bleeding or thrombotic tendency after adjusting for platelet counts and fibrinogen concentrations. A P-value <0.05 was taken as significant and all analyses were two-tailed and conducted by SPSS for Windows (version 22.0, 2014, IBM, Armonk, IL, USA) in this study.
Results
A total of 126 critically ill trauma (n=63) and non-trauma (n=63) patients were included. The characteristics of these two groups of patients are summarised in Table 1 . Infection and major surgery accounted for 48% and 24% of the nontrauma patients, respectively. The risk of an increased in vitro thrombotic tendency (59% versus 67%, P=0.461) and bleeding tendency (11% versus 10%, P=0.999) were not significantly different between the critically ill trauma and non-trauma patients. Of all the conventional coagulation blood tests assessed, thrombocytopenia and a low fibrinogen concentration were the only two factors associated with an increased in vitro bleeding tendency (both P=0.001) and thrombocytopenia was the only factor associated with a reduced risk of in vitro thrombotic tendency (21% versus 75%, P=0.001).
Platelet counts (r: 0.59, P=0.001) (Figure 1 ) and fibrinogen concentrations (r: 0.61, P=0.001) (Figure 2 ) both had a relatively linear association with MA on the TEG, but not INR or aPTT (Figures 3 and 4) . Although the non-trauma patients were older and had more organ dysfunction on the day of testing (Table 1) , there were no substantial differences between trauma and non-trauma patients in the relationships between different coagulation blood test results and MA on the TEG (Figures 1 to 4 ). An elevated C-reactive protein concentration was common in both critically ill trauma and non-trauma patients ( Symptomatic VTE occurred in ten patients (8%), with a suggestion that this was more common among the trauma patients (13% versus 3%, P=0.095), although this difference was not statistically significant. The conventional coagulation blood tests and TEG parameters were not significantly associated with occurrence of subsequent symptomatic VTE.
Discussion
This study showed that in vitro thrombotic tendency was more common than in vitro bleeding tendency in both critically ill trauma and non-trauma patients who were not actively bleeding. Thrombocytopenia and a low fibrinogen concentration were the only significant predictors of an increased risk of in vitro bleeding tendency and thrombocytopenia was the only predictor of a reduced risk of in vitro thrombotic tendency. A prolonged INR or aPTT were not significant predictors of either an increased in vitro bleeding or thrombotic tendency in either trauma and nontrauma patients. These results have some clinical implications and require further consideration.
Firstly, our result challenges the traditional dogma that a prolonged INR or aPTT result implies a patient is 'auto-anticoagulated' and is only prone to bleeding but not VTE, and hence not requiring pharmacological VTE prophylaxis 13 . Although INR and aPTT can tell us whether or not a patient is deficient in one or more pro-coagulants, these coagulation blood tests cannot assess whether this deficiency is counterbalanced by a parallel deficiency of anticoagulants, significantly limiting the use of the coagulation tests to predict whether patients with acquired coagulopathy are already 'auto-anticoagulated' or, in fact, prothrombotic 14 . Whether critically ill trauma patients who have acquired coagulopathy are prothrombotic and are associated with a similar or increased risk of VTE compared to those without acquired coagulopathy remains uncertain. Our results suggest that transfusing blood products, administering tranexamic acid, or omitting pharmacologic VTE prophylaxis in critically ill patients with asymptomatic abnormal INR or aPTT results may not only be ineffective in reducing bleeding 15, 16 , but it may possibly be harmful if the patients are prothrombotic. At a practical level, our results may also encourage clinicians to use TEG as a point-of-care test to guide VTE prophylaxis or transfusion practice in trauma patients with acquired coagulopathy and this may reduce omission of pharmacological VTE prophylaxis and unnecessary transfusion of fresh frozen plasma in critically ill trauma patients who are not actively bleeding. Recently, a randomised study showed that using the r-time on the TEG to titrate enoxaparin doses was not superior to using a standard fixed dose of enoxaparin, 30 mg twice a day, in reducing VTE in surgical and trauma patients 17 . This study was, however, limited by its small sample size (n=87), and whether the patients were prothrombotic (with a large MA on TEG) was not considered.
Secondly, our results show that platelet counts and fibrinogen concentrations are the two most important predictors of increased in vitro bleeding tendency and this is consistent with the recent evidence showing the importance of maintaining an adequate fibrinogen concentration in the setting of critical bleeding 18 . As for an increased in vitro thrombotic tendency, our results show that platelet counts appear to be most important and this is consistent with emerging evidence which supports the important role of platelets in the pathogenesis of VTE 19, 20 . Perhaps, in trauma patients who do not have active bleeding, withholding pharmacological VTE prophylaxis is probably more advisable in patients with significant thrombocytopenia than in patients with a prolonged INR or aPTT alone, if TEG or other point-of-care wholeblood testing is not available to assess the patient's in vitro bleeding and thrombotic tendency.
The final consideration is the limitations of this study. This study was underpowered to detect any association between increased in vitro thrombotic and VTE outcomes. Due to the observational nature of this study, we did not have outcome data to assess whether VTE prophylaxis guided by TEG can improve patient-centred outcomes. If we assume the risk of VTE is 20% in the standard VTE strategy group, a sample size of 219 patients per group is needed to achieve 80% power to demonstrate a 10% absolute risk reduction in VTE (from 20% to 10%) after using MA on the TEG to guide VTE prophylaxis. Finally, TEG also has significant limitations in assessing the full scheme of bleeding and thrombotic tendency. For example, it is inaccurate in detecting conditions that affect platelet adhesion (e.g. von Willebrand's disease) and the effect of aspirin or clopidogrel on clotting 12 and in the presence of hypothermia as the measurement is undertaken at 37°C. There are now also many new haematological blood tests that can be used to assess thrombotic and bleeding tendency (e.g. ROTEM®, Calibrated Automated Thrombogram, plasma-and cellderived microparticles, prothrombin fragments and thrombin/antithrombin III complexes). Whether INR and aPTT are more predictive of prothrombotic or bleeding tendency measured by these new coagulation tests remains uncertain and this merits further investigation.
Conclusion
In conclusion, increased in vitro thrombotic tendency was more common than increased bleeding tendency in critically ill trauma patients who were not having active bleeding. Platelet counts and fibrinogen concentrations were better predictors of increased in vitro thrombotic and bleeding risks than INR or aPTT. A randomised controlled trial comparing the use of MA on the TEG to guide VTE prophylaxis against using conventional coagulation blood tests alone is needed to confirm the clinical utility of TEG in preventing VTE in critically ill trauma and non-trauma patients.
